The Medical Letter on Drugs and Therapeutics
Riociguat (Adempas) for Pulmonary Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) following surgery or when surgery is not an option. It is the first drug to be approved for treatment of CTEPH.

DRUGS FOR PAH — Current management of PAH usually includes warfarin (Coumadin, and others) and furosemide (Lasix, and generics). Oral drugs approved for PAH include the phosphodiesterase type 5 (PDE5) inhibitors sildenafil (Revatio, and generics) and tadalafil (Adcirca), the endothelin receptor antagonists bosentan (Tracleer), ambrisentan (Letairis), and, most recently, macitentan (Opsumit), a nonselective endothelin receptor antagonist derived from bosentan.1 Patients with more advanced ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Riociguat (Adempas) for Pulmonary Hypertension
Article code: 1437b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian